2015
DOI: 10.1016/j.yrtph.2015.09.003
|View full text |Cite
|
Sign up to set email alerts
|

Proof of concept for a banding scheme to support risk assessments related to multi-product biologics manufacturing

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…When multiple biologics are produced in a single facility but are not used together as combination drugs, there is the risk of cross-contamination. This risk depends on the type of the drug and can be evaluated using acceptable daily exposure (ADE) values 55 . Recently, Carver proposed a banding scheme to assess the potency or toxicity of biologics; the biologics were categorized according to their toxicity 56 .…”
Section: Discussionmentioning
confidence: 99%
“…When multiple biologics are produced in a single facility but are not used together as combination drugs, there is the risk of cross-contamination. This risk depends on the type of the drug and can be evaluated using acceptable daily exposure (ADE) values 55 . Recently, Carver proposed a banding scheme to assess the potency or toxicity of biologics; the biologics were categorized according to their toxicity 56 .…”
Section: Discussionmentioning
confidence: 99%